Clinical trial Recruiting at 1 site Observational Ages 45 to 75

How EDOF lens implants change eye light sensitivity after presbyopic correction

Official title: Impact of Artificial Lighting on Visual Acuity After Presbyopia Correction With an Extended Depth of Focus Intraocular Lens: Introduction of a Modified Luminous Efficiency Function V(λ)'

Run by Democritus University of Thrace · NCT07077967 · Data updated 2026-11-12

This will test whether people aged 45–75 who had EDOF intraocular lens implants need different lighting levels to reach their best vision.

Quick facts

Study typeObservational
Ages45 Years to 75 Years
SexAll
Enrollment100 (estimated)
SponsorDemocritus University of Thrace
Academic / other
Locations1 site (Alexandroupoli, Evros)
StatusRecruiting
StartedOctober 15, 2025
Main results expectedOctober 15, 2026
Study endsDecember 15, 2026
Registry record updatedFebruary 24, 2026
Trial IDNCT07077967 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 45–75 years old who have undergone pseudophakic presbyopic correction with EDOF IOLs, have postoperative uncorrected distance visual acuity of at least 8/10, and no major ocular or systemic exclusions listed in the protocol.

Probably not a fit

Patients with significant ocular disease (e.g., glaucoma, corneal or fundus disease), diabetes, autoimmune or neurological/psychiatric conditions, prior incisional eye surgery, astigmatism >1.00 D, posterior capsule rupture or lens misalignment are unlikely to benefit from the study findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study measures how extended‑depth-of-focus (EDOF) intraocular lenses modify total eye light transmittance and the luminous efficiency function in pseudophakic patients treated for presbyopia. Participants who meet the inclusion and exclusion criteria will have their visual acuity tested at varying controlled light intensities to identify the minimum light level required to reach maximal acuity compared with full lighting. Findings will be used to model a modified luminous efficiency function specific to this patient group and to estimate task and environmental lighting adjustments. The study is conducted at the University Hospital of Alexandroupolis and enrolls patients aged 45–75 without major ocular or systemic comorbidities.

Why it matters

Potential benefit: If successful, the results could provide practical lighting recommendations to help people with EDOF IOLs achieve better everyday vision and comfort.

How similar studies have gone: Previous research has examined IOL effects on vision and light transmission in limited contexts, but a specifically modified luminous efficiency function for EDOF IOL patients is novel and not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age between 45 to 75 years

Exclusion Criteria:

* astigmatism \>1.00 diopters
* glaucoma
* former incisional eye surgery
* corneal or fundus disease
* diabetes mellitus
* autoimmune diseases
* neurological or psychiatric diseases
* posterior capsule rupture or lens misalignment
* postoperative uncorrected distance visual acuity \< 8/10.

Where it's running

  • University Hospital of Alexandroupolis
    Alexandroupoli, Evros, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.